Biotech | November 30, 2022
Lonza collaborates with AbTis to extend Bioconjugation capabilities
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
_256_384.png)
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness
40,000 visitors and representatives of more than 80 countries set to visit the show
The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Subscribe To Our Newsletter & Stay Updated
